Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 84

Sort by

Sort Order Select

Journal Articles

Updated Results from the German Mpnsg-0212 Combination Trial: Ruxolitinib Plus Pomalidomide in Myelofibrosis with Anemia

Blood (2019) 134 (Supplement_1): 672.

https://doi.org/10.1182/blood-2019-127859

Published: 2019

Journal Articles

Original Versus Generic Lenalidomide in Patients with Relapsed Multipl Myeloma: Comprasion of Effectivity and Adverse Events

Zahit Bolaman, Sehmus Ertop, Atakan Turgutkaya, Selim Cem, Ayse Hilal Eroglu Kucukerdiler, Birsen Sahip, Irfan Yavasoglu, MD

Blood (2019) 134 (Supplement_1): 5594.

https://doi.org/10.1182/blood-2019-131093

Published: 2019

Journal Articles

Ibrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in Community Clinical Practice Outside of Clinical Trials

Vladimir I. Vorobyev, MD PhD, Vera A. Zherebtsova, MD PhD, Egor I. Dubrovin, Liudmila A. Bychenkova, Lev S. Butaev, Larisa A. Muha, Yulia B. Kochkareva, Valentina L. Ivanova, Eugene A. Nikitin, MD PhD Professor, Gayane Tumyan, DMSc, MD PhD, Vadim A Doronin, MD, Oleg I. Krijanovski, MD PhD, Vadim Ptushkin, MD PhD Professor

Blood (2019) 134 (Supplement_1): 5255.

https://doi.org/10.1182/blood-2019-126430

Published: 2019

Journal Articles

Experience of Generic Imatinib As a First Line Therapy for Patients with Chronic Myeloid Leukemia in a Single Reference Institution

Gabriel Carvalho Pereira, MD, Fernanda B da Silva, BSc and MSc, Luisa Espirito Santo Oliveira, Pedro Marques Garibaldi, MD, Lorena Lobo Figueiredo-Pontes, MD PhD, Belinda Pinto Simões, MD PhD, Leonardo Carvalho Palma, MD PhD, Fabiola Traina, MD PhD

Blood (2019) 134 (Supplement_1): 5916.

https://doi.org/10.1182/blood-2019-132045

Published: 2019

Journal Articles

A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)

Anna Kalff, MBBS, Jake Shortt, MBBS FRACP FRCPA PhD, Flora Yuen, BBiomedSc, John Reynolds, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, Craig Thomas Wallington-Beddoe, BSc,MBBS,PhDFRACP,FRCPA, Patricia Walker, MBBS, BMedSci, FRACP, FRCPA, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Rosanne Dunn, PhD, Andrew Spencer, DM

Blood (2019) 134 (Supplement_1): 3144.

https://doi.org/10.1182/blood-2019-130084

Published: 2019

Journal Articles

Effects of the Switch to Generic Imatinib in a Cohort of 109 Italian CML Patients - the Gims Study

Maria Gemelli, MD, Chiara Elena, MD, Margherita Maffioli, MD, Cristina Bucelli, MD, Marianna Rossi, MD, Mattia Bacciocchi, Elena Maria Elli, MD, Maria Grazia Valsecchi, PhD, Laura Antolini, PhD, Carlo Gambacorti-Passerini, MD

Blood (2018) 132 (Supplement 1): 4266.

https://doi.org/10.1182/blood-2018-99-115208

Published: 2018

Journal Articles

Hedgehog Pathway Inhibitor for Treatment of Steroid-Refractory Sclerodermatous Chronic Graft-Versus-Host Disease (GVHD)

Ridhi Gupta, MD, Abdulwahab Albabtain, MD, Sally Arai, MD, Bernice Kwong, MD, Wen-Kai Weng, MD PhD

Blood (2018) 132 (Supplement 1): 3409.

https://doi.org/10.1182/blood-2018-99-113915

Published: 2018

Journal Articles

Tolerability and Efficacy of Post Transplant Lenalidomide Maintenance Therapy in Multiple Myeloma: A Real World Single Centre Experience

Chloe Yang, MD BS, Haiyan Jiang, PhD, Esther Masih-Khan, PhD, Christine I Chen, MD FRCP(C), Anca Prica, MD FRCP(C), Donna Reece, MD FRCP(C), Rodger Tiedemann, MBChB, PhD, Suzanne Trudel, MD FRCP(C), Vishal Kukreti, MD FRCP(C)

Blood (2017) 130 (Supplement 1): 3462.

https://doi.org/10.1182/blood.V130.Suppl_1.3462.3462

Published: 2017

Journal Articles

Persistence with Generic Imatinib for Chronic Myeloid Leukemia: A Matched Cohort Study

Adi J. Klil-Drori, MD, Hui Yin, MSc, Laurent Azoulay, PhD, Alexa Del Corpo, Michael Harnois, Michel-Olivier Gratton, Lambert Busque, MD, Sarit Assouline, MD

Blood (2017) 130 (Supplement 1): 315.

https://doi.org/10.1182/blood.V130.Suppl_1.315.315

Published: 2017

Journal Articles

Variables Associated with Patient-Reported Symptoms in Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors

Lu Yu, MD, Qian Jiang, MD

Blood (2017) 130 (Supplement 1): 1605.

https://doi.org/10.1182/blood.V130.Suppl_1.1605.1605

Published: 2017

Journal Articles

Response to Front-Line Imatinib Treatment in Children and Adolescents with CML - Data from a Large Pediatric Cohort

Blood (2017) 130 (Supplement 1): 898.

https://doi.org/10.1182/blood.V130.Suppl_1.898.898

Published: 2017

Journal Articles

Ibrutinib Is Highly Active As First Line Therapy in Symptomatic Waldenstrom's Macroglobulinemia

Blood (2017) 130 (Supplement 1): 2767.

https://doi.org/10.1182/blood.V130.Suppl_1.2767.2767

Published: 2017

Journal Articles

Efficacy and Safety of Generic Imatinib after Switching from Innovator Imatinib in Patients Treated for Chronic Myeloid Leukemia

Iman Aboudalle, MD, Hagop M. Kantarjian, MD, Jan A. Burger, MD PhD, Zeev Estrov, MD, Maro Ohanian, DO, Elias J. Jabbour, MD, Srdan Verstovsek, MD PhD, Farhad Ravandi, MBBS, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 2906.

https://doi.org/10.1182/blood.V130.Suppl_1.2906.2906

Published: 2017

Journal Articles

Comparative Risk Assessment of Imatinib, Nilotinib and Dasatinib in Randomized Controlled Trials: A Meta-Analysis

Ahmad Ghorab, MDMSc, Hagop M. Kantarjian, MD, Hesham Elhalawani, MD MS, Hoda Ahmed, MD MS, Ahmed Essam, MD, Omar Abdel-Rahman, MD PhD, Elias J. Jabbour, MD, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 2869.

https://doi.org/10.1182/blood.V130.Suppl_1.2869.2869

Published: 2017

Journal Articles

Pomalidomide in Hereditary Hemorrhagic Telangiectasia: Interim Results of a Phase I Study

Mohamed Samour, MBBS, Caner Saygin, MD, Rashid Abdallah, RN, Suman Kundu, MS, MBA, Keith R. McCrae, MD

Blood (2016) 128 (22): 210.

https://doi.org/10.1182/blood.V128.22.210.210

Published: 2016

Journal Articles

Efficacy and Safety of Nilotinib 300 Mg Twice Daily (BD) in Patients with CML in Chronic Phase (CML-CP) Who Are Intolerant to Prior BCR-ABL Tyrosine Kinase Inhibitors (TKIs): Results from the Randomized, Phase IIIb E.N.E.S.Tswift Study

Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Peter Tan, James D'Rozario, John Taper, MBBS FRACP FRCPA, Anthony Richard Powell, FRACP, MBBS, Ian Irving, Matthew P.F. Wright, MBBS, FRCPA, FRACP, Susan Branford, PhD FFSc (RCPA), David T. Yeung, BSc, MBBS, FRACP, FRCPA, Luke Anderson, Othon L Gervasio, Timothy P. Hughes, MD

Blood (2016) 128 (22): 5447.

https://doi.org/10.1182/blood.V128.22.5447.5447

Published: 2016

Journal Articles

Generic Imatinib in Chronic Myeloid Leukemia: Survival of the Cheapest

Danthala Madhav

Blood (2016) 128 (22): 630.

https://doi.org/10.1182/blood.V128.22.630.630

Published: 2016

Journal Articles

Phase 2 Trial of Smoothened (SMO) Inhibitor PF-04449913 (PF-04) in Refractory Myelodysplastic Syndromes (MDS)

Jeffrey E. Lancet, MD, Rami S Komrokji, MD, Kendra L. Sweet, MD, Vu H. Duong, MD, Kathy L McGraw, PhD, Ling Zhang, MD, Lisa Ann Nardelli, BS, Zhenjun Ma, PhD, Richard R Reich, PhD, Eric Padron, MD, Alan F List, MD

Blood (2016) 128 (22): 3174.

https://doi.org/10.1182/blood.V128.22.3174.3174

Published: 2016

Journal Articles

Single Agent Ibrutinib in CLL/SLL Patients with and without Deletion 17p

Mohammed Farooqui, DO, Janet Valdez, PA-C, Susan Soto, RN, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Francine Thomas, BS, Xin Tian, PhD, Irina Maric, Adrian Wiestner, MD PhD

Blood (2015) 126 (23): 2937.

https://doi.org/10.1182/blood.V126.23.2937.2937

Published: 2015

Journal Articles

Profile of Pediatric Chronic Myeloid Leukemia in the Era of Imatinib - a Study from a Developing Country

Rashmika Rajendran, MBBS, Catherene Cirumalar Bernard, Febe Renjitha Suman, MD, Julius Xavier Scott, DCH, MD DNB, Aruna Rajendran, MDDM, Rithika Rajendran, MBBS, Rajesh V

Blood (2015) 126 (23): 5599.

https://doi.org/10.1182/blood.V126.23.5599.5599

Published: 2015

NARROW

Updated Results from the German Mpnsg-0212 Combination Trial: Ruxolitinib Plus Pomalidomide in Myelofibrosis with Anemia

Original Versus Generic Lenalidomide in Patients with Relapsed Multipl Myeloma: Comprasion of Effectivity and Adverse Events

Ibrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in Community Clinical Practice Outside of Clinical Trials

Experience of Generic Imatinib As a First Line Therapy for Patients with Chronic Myeloid Leukemia in a Single Reference Institution

A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)

Effects of the Switch to Generic Imatinib in a Cohort of 109 Italian CML Patients - the Gims Study

Hedgehog Pathway Inhibitor for Treatment of Steroid-Refractory Sclerodermatous Chronic Graft-Versus-Host Disease (GVHD)

Tolerability and Efficacy of Post Transplant Lenalidomide Maintenance Therapy in Multiple Myeloma: A Real World Single Centre Experience

Persistence with Generic Imatinib for Chronic Myeloid Leukemia: A Matched Cohort Study

Variables Associated with Patient-Reported Symptoms in Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors

Response to Front-Line Imatinib Treatment in Children and Adolescents with CML - Data from a Large Pediatric Cohort

Ibrutinib Is Highly Active As First Line Therapy in Symptomatic Waldenstrom's Macroglobulinemia

Efficacy and Safety of Generic Imatinib after Switching from Innovator Imatinib in Patients Treated for Chronic Myeloid Leukemia

Comparative Risk Assessment of Imatinib, Nilotinib and Dasatinib in Randomized Controlled Trials: A Meta-Analysis

Pomalidomide in Hereditary Hemorrhagic Telangiectasia: Interim Results of a Phase I Study

Efficacy and Safety of Nilotinib 300 Mg Twice Daily (BD) in Patients with CML in Chronic Phase (CML-CP) Who Are Intolerant to Prior BCR-ABL Tyrosine Kinase Inhibitors (TKIs): Results from the Randomized, Phase IIIb E.N.E.S.Tswift Study

Generic Imatinib in Chronic Myeloid Leukemia: Survival of the Cheapest

Phase 2 Trial of Smoothened (SMO) Inhibitor PF-04449913 (PF-04) in Refractory Myelodysplastic Syndromes (MDS)

Single Agent Ibrutinib in CLL/SLL Patients with and without Deletion 17p

Profile of Pediatric Chronic Myeloid Leukemia in the Era of Imatinib - a Study from a Developing Country

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only